1. ALLA AKTIER
  2. NYHETER
  3. AMNIOTICS

Amniotics

Nyheter Amniotics Nyheter alla bolag
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!

Amniotics AB postpones the publication of the interim report for the second quarter until 31 August 2023

MARKN.

Amniotics has decided to postpone the publication of the interim report for the second quarter. The previously announced date for publication was Friday, 18 August. The new date for publication is Thursday, 31 August.

The postponement is due to administrative reasons.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.
Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.
Amniotics is headquartered in Lund, Sweden.
The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.
Learn more at www.amniotics.com. 

Attachments

Amniotics AB postpones the publication of the interim report for the second quarter until 31 August 2023

Datum 2023-08-17, kl 15:10
Källa MFN
Bifogade filer
Amniotics AB postpones the publication of the interim report for the second quarter until 31 August 2023